Cargando…
Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity
BACKGROUND: The response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) is impaired in up to 50% of patients due to chemoresistance, with no predictive biomarkers in clinical use. The proto-oncogene RNA-binding motif protein 3 (RBM3) has emerged as a putat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811987/ https://www.ncbi.nlm.nih.gov/pubmed/35109796 http://dx.doi.org/10.1186/s12885-021-09168-7 |
_version_ | 1784644550782877696 |
---|---|
author | Wahlin, Sara Boman, Karolina Moran, Bruce Nodin, Björn Gallagher, William M. Karnevi, Emelie Jirström, Karin |
author_facet | Wahlin, Sara Boman, Karolina Moran, Bruce Nodin, Björn Gallagher, William M. Karnevi, Emelie Jirström, Karin |
author_sort | Wahlin, Sara |
collection | PubMed |
description | BACKGROUND: The response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) is impaired in up to 50% of patients due to chemoresistance, with no predictive biomarkers in clinical use. The proto-oncogene RNA-binding motif protein 3 (RBM3) has emerged as a putative modulator of chemotherapy response in several solid tumours but has a hitherto unrecognized role in MIBC. METHODS: RBM3 protein expression level in tumour cells was assessed via immunohistochemistry in paired transurethral resection of the bladder (TURB) specimens, cystectomy specimens and lymph node metastases from a consecutive cohort of 145 patients, 65 of whom were treated with NAC. Kaplan-Meier and Cox regression analyses were applied to estimate the impact of RBM3 expression on time to recurrence (TTR), cancer-specific survival (CSS), and overall survival (OS) in strata according to NAC treatment. The effect of siRNA-mediated silencing of RBM3 on chemosensitivity was examined in RT4 and T24 human bladder carcinoma cells in vitro. Cellular functions of RBM3 were assessed using RNA-sequencing and gene ontology analysis, followed by investigation of cell cycle distribution using flow cytometry. RESULTS: RBM3 protein expression was significantly higher in TURB compared to cystectomy specimens but showed consistency between primary tumours and lymph node metastases. Patients with high-tumour specific RBM3 expression treated with NAC had a significantly reduced risk of recurrence and a prolonged CSS and OS compared to NAC-untreated patients. In high-grade T24 carcinoma cells, which expressed higher RBM3 mRNA levels compared to RT4 cells, RBM3 silencing conferred a decreased sensitivity to cisplatin and gemcitabine. Transcriptomic analysis revealed potential involvement of RBM3 in facilitating cell cycle progression, in particular G(1)/S-phase transition, and initiation of DNA replication. Furthermore, siRBM3-transfected T24 cells displayed an accumulation of cells residing in the G(1)-phase as well as altered levels of recognised regulators of G(1)-phase progression, including Cyclin D1/CDK4 and CDK2. CONCLUSIONS: The presented data highlight the potential value of RBM3 as a predictive biomarker of chemotherapy response in MIBC, which could, if prospectively validated, improve treatment stratification of patients with this aggressive disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09168-7. |
format | Online Article Text |
id | pubmed-8811987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88119872022-02-03 Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity Wahlin, Sara Boman, Karolina Moran, Bruce Nodin, Björn Gallagher, William M. Karnevi, Emelie Jirström, Karin BMC Cancer Research BACKGROUND: The response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) is impaired in up to 50% of patients due to chemoresistance, with no predictive biomarkers in clinical use. The proto-oncogene RNA-binding motif protein 3 (RBM3) has emerged as a putative modulator of chemotherapy response in several solid tumours but has a hitherto unrecognized role in MIBC. METHODS: RBM3 protein expression level in tumour cells was assessed via immunohistochemistry in paired transurethral resection of the bladder (TURB) specimens, cystectomy specimens and lymph node metastases from a consecutive cohort of 145 patients, 65 of whom were treated with NAC. Kaplan-Meier and Cox regression analyses were applied to estimate the impact of RBM3 expression on time to recurrence (TTR), cancer-specific survival (CSS), and overall survival (OS) in strata according to NAC treatment. The effect of siRNA-mediated silencing of RBM3 on chemosensitivity was examined in RT4 and T24 human bladder carcinoma cells in vitro. Cellular functions of RBM3 were assessed using RNA-sequencing and gene ontology analysis, followed by investigation of cell cycle distribution using flow cytometry. RESULTS: RBM3 protein expression was significantly higher in TURB compared to cystectomy specimens but showed consistency between primary tumours and lymph node metastases. Patients with high-tumour specific RBM3 expression treated with NAC had a significantly reduced risk of recurrence and a prolonged CSS and OS compared to NAC-untreated patients. In high-grade T24 carcinoma cells, which expressed higher RBM3 mRNA levels compared to RT4 cells, RBM3 silencing conferred a decreased sensitivity to cisplatin and gemcitabine. Transcriptomic analysis revealed potential involvement of RBM3 in facilitating cell cycle progression, in particular G(1)/S-phase transition, and initiation of DNA replication. Furthermore, siRBM3-transfected T24 cells displayed an accumulation of cells residing in the G(1)-phase as well as altered levels of recognised regulators of G(1)-phase progression, including Cyclin D1/CDK4 and CDK2. CONCLUSIONS: The presented data highlight the potential value of RBM3 as a predictive biomarker of chemotherapy response in MIBC, which could, if prospectively validated, improve treatment stratification of patients with this aggressive disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09168-7. BioMed Central 2022-02-02 /pmc/articles/PMC8811987/ /pubmed/35109796 http://dx.doi.org/10.1186/s12885-021-09168-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wahlin, Sara Boman, Karolina Moran, Bruce Nodin, Björn Gallagher, William M. Karnevi, Emelie Jirström, Karin Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity |
title | Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity |
title_full | Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity |
title_fullStr | Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity |
title_full_unstemmed | Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity |
title_short | Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity |
title_sort | pre-clinical and clinical studies on the role of rbm3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811987/ https://www.ncbi.nlm.nih.gov/pubmed/35109796 http://dx.doi.org/10.1186/s12885-021-09168-7 |
work_keys_str_mv | AT wahlinsara preclinicalandclinicalstudiesontheroleofrbm3inmuscleinvasivebladdercancerlongitudinalexpressiontranscriptomeleveleffectsandmodulationofchemosensitivity AT bomankarolina preclinicalandclinicalstudiesontheroleofrbm3inmuscleinvasivebladdercancerlongitudinalexpressiontranscriptomeleveleffectsandmodulationofchemosensitivity AT moranbruce preclinicalandclinicalstudiesontheroleofrbm3inmuscleinvasivebladdercancerlongitudinalexpressiontranscriptomeleveleffectsandmodulationofchemosensitivity AT nodinbjorn preclinicalandclinicalstudiesontheroleofrbm3inmuscleinvasivebladdercancerlongitudinalexpressiontranscriptomeleveleffectsandmodulationofchemosensitivity AT gallagherwilliamm preclinicalandclinicalstudiesontheroleofrbm3inmuscleinvasivebladdercancerlongitudinalexpressiontranscriptomeleveleffectsandmodulationofchemosensitivity AT karneviemelie preclinicalandclinicalstudiesontheroleofrbm3inmuscleinvasivebladdercancerlongitudinalexpressiontranscriptomeleveleffectsandmodulationofchemosensitivity AT jirstromkarin preclinicalandclinicalstudiesontheroleofrbm3inmuscleinvasivebladdercancerlongitudinalexpressiontranscriptomeleveleffectsandmodulationofchemosensitivity |